Loading...
Acotec Scientific Holdings Limited
6669.HK•HKSE
Healthcare
Medical - Devices
HK$12.45
HK$0.65(5.51%)

The company's financials show resilient growth, with revenue advancing from $115.39M in Q3 2023 to $146.17M in Q2 2024. Gross profit remained healthy with margins at 74% in Q2 2024 compared to 79% in Q3 2023. Operating income hit $23.12M last quarter, sustaining a consistent 16% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $21.25M. Net income rose to $19.98M, while earnings per share reached $0.07. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan